0000000001309454

AUTHOR

Sandrine Kappler-gratias

Antipoxvirus Activity Evaluation of Optimized Corroles Based on Development of Autofluorescent ANCHOR Myxoma Virus

International audience; A series of 43 antiviral corrole-based molecules have been tested on myxoma virus (Lausanne-like T1MYXV strain). An autofluorescent MYXV, with an ANCHOR cassette, has been used for the studies. A(2)B-fluorocorroles display various toxicities, from 40 being very toxic (CC50 = 1.7 mu M) to nontoxic 38 (CC50 > 50 mu M), whereas A(3)-fluorocorroles, with one to three fluorine atoms, are not toxic (with the exception of corroles 9, 10, and 22). In vitro, these compounds show a good selectivity index when used alone. Corrole 35 seems to be the most promising compound, which displays a high selectivity index with the lowest IC50. Interestingly, this "Hit" corrole is easy to…

research product

A3- and A2B-fluorocorroles: synthesis, X-ray characterization and antiviral activity evaluation against human cytomegalovirus infection

Twenty-nine fluorinated corroles were prepared, spectroscopically characterized, and studied for their antiviral activity against human cytomegalovirus infection. Six corroles were also fully characterized by X-ray crystallography giving insights on their geometrical features. The halogenated corroles reported herein exhibit significantly improved antiviral activity over their non-halogenated counterparts and over nitro-corrole analogs previously reported. Full activity of thirteen A3-corroles is achieved with four fluorine atoms present on the meso-phenyl ring reaching a selectivity index above 300. The maximum activity is achieved for A2B-corroles with selectivity indexes above 400. We th…

research product

A3- and A2B-nitrocorroles: synthesis and antiviral activity evaluation against human cytomegalovirus infection

Human cytomegalovirus (hCMV) is responsible for several pathologies impacting immunocompromised patients and can trigger life-threatening infection. Several antivirals are available and are used in the clinic, but hCMV resistant strains have appeared and patients have encountered therapeutic failure. Hence, there is a constant need for new best in class or first in class antiviral molecules. We have previously shown that nitrocorroles could be used as a potent anti-hCMV agent without acute toxicity in mice. They therefore represent an excellent platform to perform structure–activity relationship (SAR) studies and to increase efficiency or reduce toxicity. We have generated original A2B- and…

research product

CCDC 1910519: Experimental Crystal Structure Determination

Related Article: Sandrine Kappler-Gratias, Léo Bucher, Nicolas Desbois, Yoann Rousselin, Kerstin Bystricky, Claude P. Gros, Franck Gallardo|2020|RSC Med. Chem.|11|783|doi:10.1039/D0MD00127A

research product

CCDC 1910517: Experimental Crystal Structure Determination

Related Article: Sandrine Kappler-Gratias, Léo Bucher, Nicolas Desbois, Yoann Rousselin, Kerstin Bystricky, Claude P. Gros, Franck Gallardo|2020|RSC Med. Chem.|11|783|doi:10.1039/D0MD00127A

research product

CCDC 1910516: Experimental Crystal Structure Determination

Related Article: Sandrine Kappler-Gratias, Léo Bucher, Nicolas Desbois, Yoann Rousselin, Kerstin Bystricky, Claude P. Gros, Franck Gallardo|2020|RSC Med. Chem.|11|783|doi:10.1039/D0MD00127A

research product

CCDC 1910518: Experimental Crystal Structure Determination

Related Article: Sandrine Kappler-Gratias, Léo Bucher, Nicolas Desbois, Yoann Rousselin, Kerstin Bystricky, Claude P. Gros, Franck Gallardo|2020|RSC Med. Chem.|11|783|doi:10.1039/D0MD00127A

research product

CCDC 1910515: Experimental Crystal Structure Determination

Related Article: Sandrine Kappler-Gratias, Léo Bucher, Nicolas Desbois, Yoann Rousselin, Kerstin Bystricky, Claude P. Gros, Franck Gallardo|2020|RSC Med. Chem.|11|783|doi:10.1039/D0MD00127A

research product

CCDC 1910514: Experimental Crystal Structure Determination

Related Article: Sandrine Kappler-Gratias, Léo Bucher, Nicolas Desbois, Yoann Rousselin, Kerstin Bystricky, Claude P. Gros, Franck Gallardo|2020|RSC Med. Chem.|11|783|doi:10.1039/D0MD00127A

research product